1.
The Japan Glaucoma Society Guidelines for Glaucoma (4th Edition).
Nippon Ganka Gakkai Zasshi 2018;122:3-51.
2.
Suzuki Y, Yamamoto T, Araie M, et al. [Tajimi Study review]. Nippon
Ganka Gakkai Zasshi 2008;112:1039-1058.
3.
Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary
open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology
2004;111:1641-1648.
4.
Suzuki Y, Iwase A, Araie M, et al. Risk factors for open-angle
glaucoma in a Japanese population: the Tajimi Study. Ophthalmology
2006;113:1613-1617.
5.
Yamamoto T, Iwase A, Araie M, et al. The Tajimi Study report 2:
prevalence of primary angle closure and secondary glaucoma in a
Japanese population. Ophthalmology 2005;112:1661-1669.
6.
Krupin T. Physiologic basis of aqueous humor formation. The
Glaucomas 1996;251-280.
7.
Morizane Y, Morimoto N, Fujiwara A, et al. Incidence and causes of
visual impairment in Japan: the first nation-wide complete
enumeration survey of newly certified visually impaired individuals.
Jpn J Ophthalmol 2018.
8.
Ismail R, Azuara-Blanco A, Ramsay CR. Variation of clinical outcomes
used in glaucoma randomised controlled trials: a systematic review.
Br J Ophthalmol 2014;98:464-468.
9.
De Moraes CG, Liebmann JM, Levin LA. Detection and measurement
of clinically meaningful visual field progression in clinical trials for
glaucoma. Prog Retin Eye Res 2017;56:107-147.
10.
The effectiveness of intraocular pressure reduction in the treatment of
normal-tension glaucoma. Collaborative Normal-Tension Glaucoma
Study Group. Am J Ophthalmol 1998;126:498-505.
11.
Comparison of glaucomatous progression between untreated patients
with normal-tension glaucoma and patients with therapeutically
reduced intraocular pressures. Collaborative Normal-Tension
104
Glaucoma Study Group. Am J Ophthalmol 1998;126:487-497.
12.
The Advanced Glaucoma Intervention Study (AGIS): 7. The
relationship between control of intraocular pressure and visual field
deterioration.The AGIS Investigators. Am J Ophthalmol
2000;130:429-440.
13.
Chauhan BC, Mikelberg FS, Balaszi AG, et al. Canadian Glaucoma
Study: 2. risk factors for the progression of open-angle glaucoma. Arch
Ophthalmol 2008;126:1030-1036.
14.
Weinreb RN, Aung T, Medeiros FA. The pathophysiology and
treatment of glaucoma: a review. JAMA 2014;311:1901-1911.
15.
坂田 礼. 緑内障薬物治療の進歩-過去、現在、そして未来へ: 医歯薬出版
株式会社; 2017.
16.
Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by
prostaglandins applied topically to the eyes of conscious rabbits.
Invest Ophthalmol Vis Sci 1977;16:1125-1134.
17.
Resul B, Stjernschantz J, No K, et al. Phenyl-substituted
prostaglandins: potent and selective antiglaucoma agents. J Med
Chem 1993;36:243-248.
18.
Nomura S, Hashimoto M. [Pharmacological profiles of latanoprost
(Xalatan), a novel anti-glaucoma drug]. Nihon Yakurigaku Zasshi
2000;115:280-286.
19.
Moncada S, Vane JR. Pharmacology and endogenous roles of
prostaglandin endoperoxides, thromboxane A2, and prostacyclin.
Pharmacol Rev 1978;30:293-331.
20.
Narumiya S, Furuyashiki T. Fever, inflammation, pain and beyond:
prostanoid receptor research during these 25 years. FASEB J
2011;25:813-818.
21.
Saeki T, Ota T, Aihara M, Araie M. Effects of prostanoid EP agonists
on mouse intraocular pressure. Invest Ophthalmol Vis Sci
2009;50:2201-2208.
22.
Ocklind A. Effect of latanoprost on the extracellular matrix of the
ciliary muscle. A study on cultured cells and tissue sections. Exp Eye
Res 1998;67:179-191.
23.
Weinreb RN. Enhancement of scleral macromolecular permeability
105
with prostaglandins. Trans Am Ophthalmol Soc 2001;99:319-343.
24.
Mishima HK, Kiuchi Y, Takamatsu M, Rácz P, Bito LZ. Circadian
intraocular pressure management with latanoprost: diurnal and
nocturnal intraocular pressure reduction and increased uveoscleral
outflow. Surv Ophthalmol 1997;41 Suppl 2:S139-144.
25.
Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased
uveoscleral outflow as a possible mechanism of ocular hypotension
caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus
monkey. Exp Eye Res 1989;48:707-716.
26.
Alm A, Stjernschantz J. Effects on intraocular pressure and side
effects of 0.005% latanoprost applied once daily, evening or morning. A
comparison with timolol. Scandinavian Latanoprost Study Group.
Ophthalmology 1995;102:1743-1752.
27.
Aptel F, Cucherat M, Denis P. Efficacy and tolerability of
prostaglandin analogs: a meta-analysis of randomized controlled
clinical trials. J Glaucoma 2008;17:667-673.
28.
Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol
2014;8:1967-1985.
29.
Rácz P, Ruzsonyi MR, Nagy ZT, Bito LZ. Maintained intraocular
pressure reduction with once-a-day application of a new prostaglandin
F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study.
Arch Ophthalmol 1993;111:657-661.
30.
Camras CB, Siebold EC, Lustgarten JS, et al. Maintained reduction of
intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester
applied in multiple doses in ocular hypertensive and glaucoma
patients. Ophthalmology 1989;96:1329-1336; discussion 1336-1327.
31.
Alm A. Prostaglandin derivates as ocular hypotensive agents. Prog
Retin Eye Res 1998;17:291-312.
32.
Custer PL, Kent TL. Observations on prostaglandin orbitopathy.
Ophthalmic Plast Reconstr Surg 2016;32:102-105.
33.
Bearden W, Anderson R. Trichiasis associated with prostaglandin
analog use. Ophthalmic Plast Reconstr Surg 2004;20:320-322.
34.
Sharpe ED, Reynolds AC, Skuta GL, Jenkins JN, Stewart WC. The
clinical impact and incidence of periocular pigmentation associated
106
with either latanoprost or bimatoprost therapy. Curr Eye Res
2007;32:1037-1043.
35.
Wistrand PJ, Stjernschantz J, Olsson K. The incidence and
time-course of latanoprost-induced iridial pigmentation as a function
of eye color. Surv Ophthalmol 1997;41 Suppl 2:S129-138.
36.
Stjernschantz J, Alm A. Latanoprost as a new horizon in the medical
management of glaucoma. Curr Opin Ophthalmol 1996;7:11-17.
37.
Inoue K, Shiokawa M, Wakakura M, Tomita G. Deepening of the
upper eyelid sulcus caused by 5 types of prostaglandin analogs. J
Glaucoma 2013;22:626-631.
38.
Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper
eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J
Ophthalmol 2011;55:600-604.
39.
Sakata R, Shirato S, Miyata K, Aihara M. Incidence of deepening of
the upper eyelid sulcus in prostaglandin-associated periorbitopathy
with a latanoprost ophthalmic solution. Eye (Lond)
2014;28:1446-1451.
40.
Sakata R, Shirato S, Miyata K, Aihara M. Incidence of deepening of
the upper eyelid sulcus on treatment with a tafluprost ophthalmic
solution. Jpn J Ophthalmol 2014;58:212-217.
41.
Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR,
Grosskreutz CL. Periorbital changes associated with topical
bimatoprost. Ophthalmic Plast Reconstr Surg 2008;24:302-307.
42.
Sakata R, Shirato S, Miyata K, Aihara M. Recovery from deepening of
the upper eyelid sulcus after switching from bimatoprost to
latanoprost. Jpn J Ophthalmol 2013;57:179-184.
43.
Miki T, Naito T, Fujiwara M, et al. Effects of pre-surgical
administration of prostaglandin analogs on the outcome of
trabeculectomy. PLoS One 2017;12:e0181550.
44.
Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the
association between bilateral topical prostaglandin analogue use and
ocular adnexal features. PLoS One 2013;8:e61638.
45.
Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S, Group
L-PGS. A randomized trial of brimonidine versus timolol in preserving
107
visual function: results from the Low-Pressure Glaucoma Treatment
Study. Am J Ophthalmol 2011;151:671-681.
46.
Anggard E, Samuelsson B. Smooth muscle stimulationg lipids in
sheep iris. The identification of prostaglandin F2a. Prostaglandins
and related factors 21. Biochem Pharmacol 1964;13:281-283.
47.
Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y,
Narumiya S. Ligand binding specificities of the eight types and
subtypes of the mouse prostanoid receptors expressed in Chinese
hamster ovary cells. Br J Pharmacol 1997;122:217-224.
48.
Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The IOP-lowering
effects and mechanism of action of tafluprost in prostanoid
receptor-deficient mice. Br J Ophthalmol 2007;91:673-676.
49.
Crowston JG, Lindsey JD, Morris CA, Wheeler L, Medeiros FA,
Weinreb RN. Effect of bimatoprost on intraocular pressure in
prostaglandin FP receptor knockout mice. Invest Ophthalmol Vis Sci
2005;46:4571-4577.
50.
Crowston JG, Lindsey JD, Aihara M, Weinreb RN. Effect of
latanoprost on intraocular pressure in mice lacking the prostaglandin
FP receptor. Invest Ophthalmol Vis Sci 2004;45:3555-3559.
51.
Ota T, Aihara M, Narumiya S, Araie M. The effects of prostaglandin
analogues on IOP in prostanoid FP-receptor-deficient mice. Invest
Ophthalmol Vis Sci 2005;46:4159-4163.
52.
Camras CB, Podos SM. The role of endogenous prostaglandins in
clinically-used and investigational glaucoma therapy. Prog Clin Biol
Res 1989;312:459-475.
53.
Turan-Vural E, Torun-Acar B, Acar S. Effect of ketorolac add-on
treatment on intra-ocular pressure in glaucoma patients receiving
prostaglandin analogues. Ophthalmologica 2012;227:205-209.
54.
Yousufzai SY, Ye Z, Abdel-Latif AA. Prostaglandin F2 alpha and its
analogs induce release of endogenous prostaglandins in iris and ciliary
muscles isolated from cat and other mammalian species. Exp Eye Res
1996;63:305-310.
55.
Chiba T, Kashiwagi K, Chiba N, Tsukahara S. Effect of non-steroidal
anti-inflammatory ophthalmic solution on intraocular pressure
108
reduction by latanoprost in patients with primary open angle
glaucoma or ocular hypertension. Br J Ophthalmol 2006;90:314-317.
56.
Kashiwagi K, Tsukahara S. Effect of non-steroidal anti-inflammatory
ophthalmic solution on intraocular pressure reduction by latanoprost.
Br J Ophthalmol 2003;87:297-301.
57.
Crawford KS, Kaufman PL. Dose-related effects of prostaglandin F2
alpha isopropylester on intraocular pressure, refraction, and pupil
diameter in monkeys. Invest Ophthalmol Vis Sci 1991;32:510-519.
58.
Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases
uveoscleral outflow in the cynomolgus monkey. Exp Eye Res
1989;49:389-402.
59.
Acar U, Yıldız EH, Ergintürk Acar D, et al. Posttraumatic intraocular
pressure elevation and associated factors in patients with zone I open
globe injuries. Ulus Travma Acil Cerrahi Derg 2013;19:115-118.
60.
Mao Z, Chen XB, Zhong YM, Guo XX, Liu X. Damage to the
blood-aqueous barrier in ocular blunt trauma and its association with
intraocular pressure elevation. Ophthalmic Res 2016;56:92-97.
61.
Paterson CA, Eakins KE, Paterson E, Jenkins RM, Ishikawa R. The
ocular hypertensive response following experimental acid burns in the
rabbit eye. Invest Ophthalmol Vis Sci 1979;18:67-74.
62.
Perkins ES. Prostaglandins and ocular trauma. Adv Ophthalmol
1977;34:149-152.
63.
Hayashi K, Yoshida M, Manabe SI, Yoshimura K. Prophylactic effect
of oral acetazolamide against intraocular pressure elevation after
cataract surgery in eyes with glaucoma. Ophthalmology
2017;124:701-708.
64.
Lu J, English R, Nadelstein B, et al. Comparison of topically applied
flurbiprofen or bromfenac ophthalmic solution on post-operative
ocular hypertension in canine patients following cataract surgery. Vet
Ophthalmol 2017;20:107-113.
65.
Matusow RB, Herring IP, Pickett JP, Henao-Guerrero N, Werre SR.
Effects of perioperative topical dorzolamide hydrochloride-timolol
maleate administration on incidence and severity of postoperative
ocular hypertension in dogs undergoing cataract extraction by
109
phacoemulsification. J Am Vet Med Assoc 2016;249:1040-1052.
66.
Podos SM. Effect of dipyridamole on prostaglandin-induced ocular
hypertension in rabbits. Invest Ophthalmol Vis Sci 1979;18:646-648.
67.
Sugimoto Y, Yamasaki A, Segi E, et al. Failure of parturition in mice
lacking the prostaglandin F receptor. Science 1997;277:681-683.
68.
Ushikubi F, Sugimoto Y, Ichikawa A, Narumiya S. Roles of
prostanoids revealed from studies using mice lacking specific
prostanoid receptors. Jpn J Pharmacol 2000;83:279-285.
69.
Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular
hypotensive FP prostaglandin (PG) analogs: PG receptor subtype
binding affinities and selectivities, and agonist potencies at FP and
other PG receptors in cultured cells. J Ocul Pharmacol Ther
2003;19:501-515.
70.
Aihara M, Lindsey JD, Weinreb RN. Reduction of intraocular pressure
in mouse eyes treated with latanoprost. Invest Ophthalmol Vis Sci
2002;43:146-150.
71.
Tsuboi K, Sugimoto Y, Iwane A, Yamamoto K, Yamamoto S, Ichikawa
A. Uterine expression of prostaglandin H2 synthase in late pregnancy
and during parturition in prostaglandin F receptor-deficient mice.
Endocrinology 2000;141:315-324.
72.
Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus
from topical bimatoprost therapy. J Ocul Pharmacol Ther
2009;25:471-472.
73.
Jayaprakasam A, Ghazi-Nouri S. Periorbital fat atrophy - an
unfamiliar side effect of prostaglandin analogues. Orbit
2010;29:357-359.
74.
Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use
of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol
2011;55:22-27.
75.
Spiegelman BM, Flier JS. Obesity and the regulation of energy
balance. Cell 2001;104:531-543.
76.
Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin
Endocrinol Metab 2004;89:2548-2556.
77.
Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell
110
turnover in humans. Nature 2008;453:783-787.
78.
Arner P. Fat tissue growth and development in humans. Nestle Nutr
Inst Workshop Ser 2018;89:37-45.
79.
Evans RM, Barish GD, Wang YX. PPARs and the complex journey to
obesity. Nat Med 2004;10:355-361.
80.
Fujimori K, Aritake K, Urade Y. A novel pathway to enhance
adipocyte differentiation of 3T3-L1 cells by up-regulation of
lipocalin-type prostaglandin D synthase mediated by liver X
receptor-activated sterol regulatory element-binding protein-1c. J Biol
Chem 2007;282:18458-18466.
81.
Miller CW, Casimir DA, Ntambi JM. The mechanism of inhibition of
3T3-L1 preadipocyte differentiation by prostaglandin F2alpha.
Endocrinology 1996;137:5641-5650.
82.
Choi HY, Lee JE, Lee JW, Park HJ, Jung JH. In vitro study of
antiadipogenic profile of latanoprost, travoprost, bimatoprost, and
tafluprost in human orbital preadiopocytes. J Ocul Pharmacol Ther
2012;28:146-152.
83.
Seibold LK, Ammar DA, Kahook MY. Acute effects of glaucoma
medications and benzalkonium chloride on pre-adipocyte proliferation
and adipocyte cytotoxicity in vitro. Curr Eye Res 2013;38:70-74.
84.
Reed BC, Lane MD. Insulin receptor synthesis and turnover in
differentiating 3T3-L1 preadipocytes. Proc Natl Acad Sci U S A
1980;77:285-289.
85.
Woodward DF, Krauss AH, Chen J, et al. The pharmacology of
bimatoprost (Lumigan). Surv Ophthalmol 2001;45 Suppl 4:S337-345.
86.
Hellberg MR, Sallee VL, McLaughlin MA, et al. Preclinical efficacy of
travoprost, a potent and selective FP prostaglandin receptor agonist. J
Ocul Pharmacol Ther 2001;17:421-432.
87.
Liang Y, Woodward DF, Guzman VM, et al. Identification and
pharmacological characterization of the prostaglandin FP receptor
and FP receptor variant complexes. Br J Pharmacol
2008;154:1079-1093.
88.
Tsuruma K, Tanaka Y, Shimazawa M, Mashima Y, Hara H.
Unoprostone reduces oxidative stress- and light-induced retinal cell
111
death, and phagocytotic dysfunction, by activating BK channels. Mol
Vis 2011;17:3556-3565.
89.
Yu L, Eaton AF, Yue Q, et al. Unoprostone activation of BK (KCa1.1)
channel splice variants. Biochim Biophys Acta 2015;1848:2859-2867.
90.
Cuppoletti J, Malinowska DH, Tewari KP, Chakrabarti J, Ueno R.
Unoprostone isopropyl and metabolite M1 activate BK channels and
prevent ET-1-induced [Ca²⁺]i increases in human trabecular
meshwork and smooth muscle. Invest Ophthalmol Vis Sci
2012;53:5178-5189.
91.
Green H, Kehinde O. An established preadipose cell line and its
differentiation in culture. II. Factors affecting the adipose conversion.
Cell 1975;5:19-27.
92.
Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for
normal tension glaucoma. Ophthalmology 2009;116:1243-1249.
93.
van der Valk R, Webers CA, Lumley T, Hendrikse F, Prins MH,
Schouten JS. A network meta-analysis combined direct and indirect
comparisons between glaucoma drugs to rank effectiveness in
lowering intraocular pressure. J Clin Epidemiol 2009;62:1279-1283.
94.
Sharif NA, Crider JY, Husain S, Kaddour-Djebbar I, Ansari HR,
Abdel-Latif AA. Human ciliary muscle cell responses to FP-class
prostaglandin analogs: phosphoinositide hydrolysis, intracellular
Ca2+ mobilization and MAP kinase activation. J Ocul Pharmacol Ther
2003;19:437-455.
95.
Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological
characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor
agonist, as an ocular hypotensive drug. Exp Eye Res 2004;78:767-776.
96.
Smid SD. Role of prostaglandins and specific place in therapy of
bimatoprost in the treatment of elevated intraocular pressure and
ocular hypertension: A closer look at the agonist properties of
bimatoprost and the prostamides. Clin Ophthalmol 2009;3:663-670.
97.
Faulkner R, Sharif NA, Orr S, et al. Aqueous humor concentrations of
bimatoprost free acid, bimatoprost and travoprost free acid in cataract
surgical patients administered multiple topical ocular doses of
LUMIGAN or TRAVATAN. J Ocul Pharmacol Ther 2010;26:147-156.
112
98.
Hellberg MR, Ke TL, Haggard K, Klimko PG, Dean TR, Graff G. The
hydrolysis of the prostaglandin analog prodrug bimatoprost to
17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue. J
Ocul Pharmacol Ther 2003;19:97-103.
99.
Kanamori A, Naka M, Fukuda M, Nakamura M, Negi A. Latanoprost
protects rat retinal ganglion cells from apoptosis in vitro and in vivo.
Exp Eye Res 2009;88:535-541.
100.
Kudo H, Nakazawa T, Shimura M, et al. Neuroprotective effect of
latanoprost on rat retinal ganglion cells. Graefes Arch Clin Exp
Ophthalmol 2006;244:1003-1009.
101.
Vidal L, Díaz F, Villena A, Moreno M, Campos JG, Pérez de Vargas I.
Reaction of Müller cells in an experimental rat model of increased
intraocular pressure following timolol, latanoprost and brimonidine.
Brain Res Bull 2010;82:18-24.
102.
Hernández M, Urcola JH, Vecino E. Retinal ganglion cell
neuroprotection in a rat model of glaucoma following brimonidine,
latanoprost or combined treatments. Exp Eye Res 2008;86:798-806.
103.
Uchida S, Suzuki Y, Araie M, Kashiwagi K, Otori Y, Sakuragawa N.
Factors secreted by human amniotic epithelial cells promote the
survival of rat retinal ganglion cells. Neurosci Lett 2003;341:1-4.
104.
Otori Y, Wei JY, Barnstable CJ. Neurotoxic effects of low doses of
glutamate on purified rat retinal ganglion cells. Invest Ophthalmol
Vis Sci 1998;39:972-981.
105.
Chen YN, Yamada H, Mao W, Matsuyama S, Aihara M, Araie M.
Hypoxia-induced retinal ganglion cell death and the neuroprotective
effects of beta-adrenergic antagonists. Brain Res 2007;1148:28-37.
Epub 2007 Feb 2022.
106.
Schutte B, Nuydens R, Geerts H, Ramaekers F. Annexin V binding
assay as a tool to measure apoptosis in differentiated neuronal cells. J
Neurosci Methods 1998;86:63-69.
107.
Tezel G, Yang X. Caspase-independent component of retinal ganglion
cell death, in vitro. Invest Ophthalmol Vis Sci 2004;45:4049-4059.
108.
Emre S, Gul M, Ates B, et al. Comparison of the protective effects of
prostaglandin analogues in the ischemia and reperfusion model of
113
rabbit eyes. Exp Anim 2009;58:505-513.
109.
Kurashima H, Watabe H, Sato N, Abe S, Ishida N, Yoshitomi T.
Effects of prostaglandin F(2α) analogues on endothelin-1-induced
impairment of rabbit ocular blood flow: comparison among tafluprost,
travoprost, and latanoprost. Exp Eye Res 2010;91:853-859.
110.
Akaishi T, Kurashima H, Odani-Kawabata N, Ishida N, Nakamura M.
Effects of repeated administrations of tafluprost, latanoprost, and
travoprost on optic nerve head blood flow in conscious normal rabbits.
J Ocul Pharmacol Ther 2010;26:181-186.
111.
Cantor LB, Hoop J, Wudunn D, et al. Levels of bimatoprost acid in the
aqueous humour after bimatoprost treatment of patients with cataract.
Br J Ophthalmol 2007;91:629-632.
112.
Cuppoletti J, Malinowska DH, Tewari KP, Chakrabarti J, Ueno R.
Cellular and molecular effects of unoprostone as a BK channel
activator. Biochim Biophys Acta 2007;1768:1083-1092.
113.
Hutchinson AJ, Chou CL, Israel DD, Xu W, Regan JW. Activation of
EP2 prostanoid receptors in human glial cell lines stimulates the
secretion of BDNF. Neurochem Int 2009;54:439-446.
114.
Lee EO, Shin YJ, Chong YH. Mechanisms involved in prostaglandin
E2-mediated neuroprotection against TNF-alpha: possible
involvement of multiple signal transduction and beta-catenin/T-cell
factor. J Neuroimmunol 2004;155:21-31.
115.
Jiang J, Ganesh T, Du Y, et al. Neuroprotection by selective allosteric
potentiators of the EP2 prostaglandin receptor. Proc Natl Acad Sci U S
A 2010;107:2307-2312.
116.
Liu D, Wu L, Breyer R, Mattson MP, Andreasson K. Neuroprotection
by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann
Neurol 2005;57:758-761.
117.
McCullough L, Wu L, Haughey N, et al. Neuroprotective function of
the PGE2 EP2 receptor in cerebral ischemia. J Neurosci
2004;24:257-268.
118.
Mohan S, Narumiya S, Doré S. Neuroprotective role of prostaglandin
PGE2 EP2 receptor in hemin-mediated toxicity. Neurotoxicology
2015;46:53-59.
114
119.
Bilak M, Wu L, Wang Q, et al. PGE2 receptors rescue motor neurons
in a model of amyotrophic lateral sclerosis. Ann Neurol
2004;56:240-248.
120.
Jiang J, Dingledine R. Prostaglandin receptor EP2 in the crosshairs of
anti-inflammation, anti-cancer, and neuroprotection. Trends
Pharmacol Sci 2013;34:413-423.
121.
Echeverria V, Clerman A, Doré S. Stimulation of PGE receptors EP2
and EP4 protects cultured neurons against oxidative stress and cell
death following beta-amyloid exposure. Eur J Neurosci
2005;22:2199-2206.
122.
Ahmad AS, Zhuang H, Echeverria V, Doré S. Stimulation of
prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J
Neurotrauma 2006;23:1895-1903.
123.
Tian X, Ji C, Luo Y, et al. PGE2-EP3 signaling pathway contributes to
protective effects of misoprostol on cerebral injury in APP/PS1 mice.
Oncotarget 2016;7:25304-25314.
124.
Pradhan SS, Salinas K, Garduno AC, et al. Anti-inflammatory and
neuroprotective effects of PGE. J Neuroimmune Pharmacol
2017;12:292-304.
125.
Akram A, Gibson CL, Grubb BD. Neuroprotection mediated by the
EP₄ receptor avoids the detrimental side effects of COX-2 inhibitors
following ischaemic injury. Neuropharmacology 2013;65:165-172.
126.
Ahmad AS, Ahmad M, de Brum-Fernandes AJ, Doré S. Prostaglandin
EP4 receptor agonist protects against acute neurotoxicity. Brain Res
2005;1066:71-77.
127.
Zhao X, Wu T, Chang CF, et al. Toxic role of prostaglandin E2 receptor
EP1 after intracerebral hemorrhage in mice. Brain Behav Immun
2015;46:293-310.
128.
Carlson NG, Rojas MA, Black JD, et al. Microglial inhibition of
neuroprotection by antagonists of the EP1 prostaglandin E2 receptor.
J Neuroinflammation 2009;6:5.
129.
Zhen G, Kim YT, Li RC, et al. PGE2 EP1 receptor exacerbated
neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's
disease. Neurobiol Aging 2012;33:2215-2219.
115
130.
Kawano T, Anrather J, Zhou P, et al. Prostaglandin E2 EP1 receptors:
downstream effectors of COX-2 neurotoxicity. Nat Med
2006;12:225-229.
131.
Van Bergen NJ, Wood JP, Chidlow G, et al. Recharacterization of the
RGC-5 retinal ganglion cell line. Invest Ophthalmol Vis Sci
2009;50:4267-4272. Epub 2009 May 4214.
132.
Ohashi M, Mayama C, Ishii K, Araie M. Effects of topical travoprost
and unoprostone on optic nerve head circulation in normal rabbits.
Curr Eye Res 2007;32:743-749.
133.
Alagoz G, Gürel K, Bayer A, Serin D, Celebi S, Kukner S. A
comparative study of bimatoprost and travoprost: effect on intraocular
pressure and ocular circulation in newly diagnosed glaucoma patients.
Ophthalmologica 2008;222:88-95.
134.
Koz OG, Ozsoy A, Yarangumeli A, Kose SK, Kural G. Comparison of
the effects of travoprost, latanoprost and bimatoprost on ocular
circulation: a 6-month clinical trial. Acta Ophthalmol Scand
2007;85:838-843.
135.
Harris A, Garzozi HJ, McCranor L, Rechtman E, Yung CW, Siesky B.
The effect of latanoprost on ocular blood flow. Int Ophthalmol
2009;29:19-26.
136.
Inan UU, Ermis SS, Yücel A, Oztürk F. The effects of latanoprost and
brimonidine on blood flow velocity of the retrobulbar vessels: a
3-month clinical trial. Acta Ophthalmol Scand 2003;81:155-160.
137.
Gherghel D, Hosking SL, Cunliffe IA, Armstrong RA. First-line
therapy with latanoprost 0.005% results in improved ocular
circulation in newly diagnosed primary open-angle glaucoma patients:
a prospective, 6-month, open-label study. Eye (Lond) 2008;22:363-369.
138.
Akarsu C, Bilgili YK, Taner P, Unal B, Ergin A. Short-term effect of
latanoprost on ocular circulation in ocular hypertension. Clin Exp
Ophthalmol 2004;32:373-377.
139.
Prasanna G, Carreiro S, Anderson S, et al. Effect of PF-04217329 a
prodrug of a selective prostaglandin EP(2) agonist on intraocular
pressure in preclinical models of glaucoma. Exp Eye Res
2011;93:256-264.
116
140.
Schachar RA, Raber S, Courtney R, Zhang M. A phase 2, randomized,
dose-response trial of taprenepag isopropyl (PF-04217329) versus
latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
Curr Eye Res 2011;36:809-817.
141.
Fuwa M, Toris CB, Fan S, et al. Effects of a novel selective EP2
receptor agonist, omidenepag isopropyl, on aqueous humor dynamics
in laser-induced ocular hypertensive monkeys. J Ocul Pharmacol Ther
2018;34:531-537.
142.
Iwamura R, Tanaka M, Okanari E, et al. Identification of a selective,
non-prostanoid EP2 receptor agonist for the treatment of glaucoma:
omidenepag and its prodrug omidenepag isopropyl. J Med Chem
2018;61:6869-6891.
143.
Kirihara T, Taniguchi T, Yamamura K, et al. Pharmacologic
characterization of omidenepag isopropyl, a novel selective EP2
receptor Aaonist, as an ocular hypotensive agent. Invest Ophthalmol
Vis Sci 2018;59:145-153.
144.
Berlin MS, Rowe-Rendleman C, Ahmed I, et al. EP3/FP dual receptor
agonist ONO-9054 administered morning or evening to patients with
open-angle glaucoma or ocular hypertension: results of a randomised
crossover study. Br J Ophthalmol 2016;100:843-847.
145.
Harris A, Ward CL, Rowe-Rendleman CL, et al. Ocular hypotensive
effect of ONO-9054, an EP3/FP receptor agonist: Results of a
randomized, placebo-controlled, dose escalation study. J Glaucoma
2016;25:e826-e833.
146.
Yamane S, Karakawa T, Nakayama S, et al. IOP-lowering effect of
ONO-9054, a novel dual agonist of prostanoid EP3 and FP receptors,
in monkeys. Invest Ophthalmol Vis Sci 2015;56:2547-2552.
147.
Suto F, Rowe-Rendleman CL, Ouchi T, Jamil A, Wood A, Ward CL. A
novel dual agonist of EP3 and FP receptors for OAG and OHT: Safety,
pharmacokinetics, and pharmacodynamics of ONO-9054 in healthy
volunteers. Invest Ophthalmol Vis Sci 2015;56:7963-7970.
148.
Schlötzer-Schrehardt U, Zenkel M, Nüsing RM. Expression and
localization of FP and EP prostanoid receptor subtypes in human
ocular tissues. Invest Ophthalmol Vis Sci 2002;43:1475-1487.
117
149. Aihara M, Lindsey JD, Weinreb RN. Aqueous humor dynamics in mice.
Invest Ophthalmol Vis Sci 2003;44:5168-5173.
150.
Barany EH. Simultaneous measurement of changing intraocular
pressure and outflow facility in the vervet monkey by constant
pressure infusion. Invest Ophthalmol 1964;3:135-143.
151.
Crowston JG, Aihara M, Lindsey JD, Weinreb RN. Effect of
latanoprost on outflow facility in the mouse. Invest Ophthalmol Vis
Sci 2004;45:2240-2245.
152.
Bill A. Conventional and uveo-scleral drainage of aqueous humour in
the cynomolgus monkey (Macaca irus) at normal and high intraocular
pressures. Exp Eye Res 1966;5:45-54.
153.
Pederson JE, Gaasterland DE, MacLellan HM. Uveoscleral aqueous
outflow in the rhesus monkey: importance of uveal reabsorption.
Invest Ophthalmol Vis Sci 1977;16:1008-1007.
154.
Nakajima T, Matsugi T, Goto W, et al. New fluoroprostaglandin
F(2alpha) derivatives with prostanoid FP-receptor agonistic activity
as potent ocular-hypotensive agents. Biol Pharm Bull
2003;26:1691-1695.
155.
Ota T, Murata H, Sugimoto E, Aihara M, Araie M. Prostaglandin
analogues and mouse intraocular pressure: effects of tafluprost,
latanoprost, travoprost, and unoprostone, considering 24-hour
variation. Invest Ophthalmol Vis Sci 2005;46:2006-2011.
156.
Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal
ocular hypotensive efficacy of travoprost and latanoprost over a
44-hour period in patients with elevated intraocular pressure. Clin
Ther 2004;26:84-91.
157.
Özyol P, Özyol E, Erdoğan BD. The Interaction of Nepafenac and
Prostaglandin Analogs in Primary Open-angle Glaucoma Patients. J
Glaucoma 2016;25:e145-149.
158.
Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The effects of
prostaglandin analogues on prostanoid EP1, EP2, and EP3
receptor-deficient mice. Invest Ophthalmol Vis Sci 2006;47:3395-3399.
159.
Takamatsu M, Hotehama Y, Goh Y, Mishima HK. Localization of
prostaglandin E receptor subtypes in the ciliary body of mouse eye.
118
Exp Eye Res 2000;70:623-628.
160.
Biswas S, Bhattacherjee P, Paterson CA. Prostaglandin E2 receptor
subtypes, EP1, EP2, EP3 and EP4 in human and mouse ocular
tissues--a comparative immunohistochemical study. Prostaglandins
Leukot Essent Fatty Acids 2004;71:277-288.
161.
Ito S, Sakamoto K, Mochizuki-Oda N, et al. Prostaglandin F2 alpha
receptor is coupled to Gq in cDNA-transfected Chinese hamster ovary
cells. Biochem Biophys Res Commun 1994;200:756-762.
162.
Sugimoto Y, Namba T, Honda ...
論文の公開元へ
